BeiGene is a global biopharmaceutical company focusing on developing and commercializing innovative molecularly targeted and immune-oncology drugs for the treatment of cancer. By strengthening independent research and development capabilities, BeiGene accelerates the development of diverse and innovative drug profiles including more than 40 clinical drug candidates. With more than 8,000 employees worldwide, BeiGene is committed to extend their access to medicines of more than 2 billion people worldwide by 2030.
ISS China has been appointed by BeiGene since March 2021 to provide technical services for its Shanghai R&D center. ISS offers a stable environment for bacteria laboratories, including technical support for high-voltage and low voltage electrical currents, laboratory HVAC systems, etc. Recently, ISS China is honored to extend our service scope to a new R&D building and its sewage station.
Real Estate needs from life science industry on the rise
Driven by innovation and years of development, China has become a pioneer in the global life science industry. Looking ahead, China’s life science industry is expected to prosper further, supported by strong market demand, supportive government policy, greater talent acquisition, and sustained capital inflows.
As a talent center, Shanghai clusters 70% of the domestic life science talents, especially high-end and comprehensive talents. Therefore, BeiGene finally set its foot on Shanghai Waigaoqiao Biomedical Industrial Park when laying out its second R&D center. BeiGene, who has made great investment on R&D, has designed its Shanghai Pharmaceutical R&D Center, with a total area of more than 6,000 SQM. With biological laboratories, sterile laboratories, animal and plant embryo laboratories and other facilities, BeiGene shows ambition to leading innovation.
